Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Articles online first > Journal of Neurosurgical Sciences 2021 Jun 10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Journal of Neurosurgical Sciences 2021 Jun 10

DOI: 10.23736/S0390-5616.21.05266-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury

Mohammad SHIMIA 1, Arad IRANMEHR 2, Amir VALIZADEH 2, Farhad MIRZAEI 2, Mohamad NAMVAR 2, Ebrahim RAFIEI 1, Ahsan RAHIMI 1, Aida KHADIVI 2, Kamkar AEINFAR 2

1 Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, Iran; 2 Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran


PDF


BACKGROUND: Considering the known derangements in the dopaminergic neurotransmitter systems following traumatic brain injury (TBI), dopamine agonists are used as a pharmacologic option. In this study, we evaluate the effects of Amantadine Hydrochloride on the functional improvement of severe TBI patients.
METHODS: Within a triple-blinded (patients, intervention administrators, and outcome assessors) placebo-controlled randomized clinical trial, we evaluated the effects of Amantadine (100mg BD (twice a day) for 14 days, then 150mg BD for another 7 days, and 200mg BD for another 21 days) on outcome measurements of weekly mean Glasgow Outcome Scale (GOS) and Disability Rating Scale (DRS), through six weeks of trial for 57 patients (29 Amantadine, 28 placeboes) with severe TBI admitted in our hospital.
RESULTS: Although both groups had improvement in their DRS, the change from baseline was significantly better in the Amantadine group (10.88 ± 5.24 for Amantadine vs. 8.04 ± 4.07 for placebo, p = 0.015). No significant difference was observed between groups for GOS (1.04 ± 0.55 for Amantadine vs. 1.12 ± 1.05 for placebo, P = 0.966).
CONCLUSIONS: Based on our findings, Amantadine Hydrochloride might improve the speed of functional ability improvement in severe TBI patients, evaluated by DRS, and is also well tolerated by patients. Although, there were some limitations in this study, including small sample size, short time interval, not providing a wash-off period and invalidity of GOS for measuring recovery rates in short-term periods.


KEY WORDS: Amantadine; Brain injuries traumatic; Dopamine; Diffuse axonal injury

top of page